Outpatient autologous stem cell transplantation in Royal Hobart Hospital, Tasmania: a single‐centre, retrospective review in the Australian setting
暂无分享,去创建一个
R. Harrup | S. Ragg | A. Johnston | X. Tan | Chang Yang Yew
[1] I. Irving,et al. A 14‐year retrospective analysis of indications and outcomes of autologous haemopoietic stem cell transplantation in regional Queensland: a single‐centre experience , 2020, Internal medicine journal.
[2] D. Pilcher,et al. The financial cost of intensive care in Australia: a multicentre registry study , 2019, The Medical journal of Australia.
[3] M. Jädersten,et al. The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016 , 2019, Experimental Hematology & Oncology.
[4] S. Parmar,et al. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma , 2017, European journal of haematology.
[5] F. Morabito,et al. Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity‐based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model , 2017, Clinical lymphoma, myeloma & leukemia.
[6] A. Clemmons,et al. Mixed outpatient–inpatient autologous stem cell transplant for multiple myeloma: A cost-saving initiative in a resource constrained environment , 2017, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[7] L. Koh,et al. Safety and cost-effectiveness of outpatient autologous transplantation for multiple myeloma in Asia: single-center perspective from Singapore , 2017, Bone Marrow Transplantation.
[8] J. Friedberg,et al. Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost‐effective , 2016, Cancer medicine.
[9] J. Nates,et al. Intensive care outcomes in adult hematopoietic stem cell transplantation patients. , 2016, World journal of clinical oncology.
[10] D. Porter,et al. Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma. , 2015, Clinical lymphoma, myeloma & leukemia.
[11] D. Dingli,et al. How we manage autologous stem cell transplantation for patients with multiple myeloma. , 2014, Blood.
[12] H. Nakasone,et al. Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials. , 2014, The Journal of infection.
[13] F. Ferrara,et al. Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] O. Ballester,et al. Frontline Therapy for Multiple Myeloma: A Concise Review of the Evidence Based on Randomized Clinical Trials , 2013, Cancer investigation.
[15] G. Sauvageau,et al. Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] B. Esterni,et al. Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs , 2012, Bone Marrow Transplantation.
[17] G. Morgan,et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). , 2011, Blood.
[18] S. Lapinsky,et al. Predictors of mortality in patients undergoing autologous hematopoietic cell transplantation admitted to the intensive care unit , 2009, Bone Marrow Transplantation.
[19] H. Atkins,et al. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma , 2006, Annals of Hematology.
[20] I. Kerridge,et al. Hospital in the home (HITH) care following autologous stem cell transplantation for lymphoma and multiple myeloma. , 2006, The Australian journal of advanced nursing : a quarterly publication of the Royal Australian Nursing Federation.
[21] N. Puig,et al. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation , 2006, Leukemia & lymphoma.
[22] J. Cooney,et al. Infections in patients managed at home during autologous stem cell transplantation for lymphoma and multiple myeloma , 1999, Bone Marrow Transplantation.
[23] R. Salazar,et al. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation , 1999, Bone Marrow Transplantation.
[24] C. Huber,et al. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation , 1997, Bone Marrow Transplantation.
[25] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .
[26] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.
[27] D C Linch,et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] D. Winfield,et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.